LYRA
Lyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.20
+0.00%Margins
Gross margin
0.0%
EBITDA margin
-7794.5%
EBIT margin
-7794.5%
Net margin
-7266.1%
FCF margin
-7280.2%
269.8%
Return on equity
-80.1%
Return on assets
-158.7%
Return on invested capital
0.01x
Asset turnover
-$28.9M
Cash from operations
$8.99
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Dec 1, 2025